Loading people...
Kurt von Emster is the Managing Partner at Abingworth LLP, based in Menlo Park, California. He brings over 30 years of life sciences investment experience across public and private markets, having previously co-founded venBio in 2009 and served as a General Partner at MPM Capital. Earlier in his career, he worked extensively as a Biotechnology and Healthcare Analyst and Portfolio Manager at Franklin Templeton. After joining Abingworth in January 2015, he transitioned to his current leadership role in January 2026 amid broader organizational changes involving Carlyle. He actively manages investments and holds board positions at several portfolio companies, including CymaBay, Iambic, Jasper, Orbus, SFJ Pharmaceuticals, and Tizona Therapeutics. Holding a Bachelor of Arts in Business and Economics, his primary professional focus remains on scaling clinical-stage biotechnology and healthcare enterprises throughout the United States market.
Kurt von Emster stands as a prominent figure in the global life sciences investment landscape, currently serving as a Managing Partner at Abingworth, a renowned transatlantic venture capital firm. With a career spanning decades, von Emster has dedicated his expertise to fostering innovation within the biotechnology, pharmaceutical, and medical technology sectors, contributing significantly to the development of novel therapies and healthcare solutions.
At Abingworth, Kurt von Emster is instrumental in shaping the firm's investment strategy and portfolio. His role involves leading due diligence, deal sourcing, and portfolio management for a diverse range of companies, from nascent startups to more mature, late-stage enterprises. He is particularly focused on identifying companies with disruptive technologies and strong scientific foundations that have the potential to address critical unmet medical needs across various therapeutic areas, including oncology, immunology, neurology, and rare diseases. His strategic insights help guide these companies through crucial development milestones, from preclinical research to clinical trials and eventual market entry, maximizing their potential for success.
Von Emster's extensive career background provides a deep well of experience in healthcare investment. Before joining Abingworth, he held significant positions at other leading investment firms, where he honed his skills in venture capital and public equity investing within the life sciences. This diverse experience has equipped him with a comprehensive understanding of the entire drug development lifecycle, regulatory pathways, and market dynamics, making him a valuable partner for entrepreneurs and a discerning investor. His analytical rigor and commitment to scientific excellence are hallmarks of his investment approach, consistently seeking out opportunities that promise both innovation and strong commercial viability.
While specific individual investment details are often proprietary, Kurt von Emster has been a key contributor to Abingworth's impressive track record of backing successful life sciences companies. Abingworth's portfolio frequently includes companies that have gone on to achieve significant clinical breakthroughs, secure major partnerships, or successfully exit through IPOs or acquisitions, bringing life-changing treatments to patients worldwide. His work at Abingworth exemplifies a commitment to not only financial returns but also to advancing human health through strategic capital deployment. His leadership continues to reinforce Abingworth's position as a preferred partner for innovative life sciences ventures seeking growth capital and strategic guidance.
Kurt von Emster is a highly experienced Managing Partner at Abingworth, a leading global life sciences venture capital firm. He is known for his significant contributions to investing in and developing innovative biotechnology and pharmaceutical companies.
Kurt von Emster primarily invests in the life sciences sector, focusing on biotechnology, pharmaceuticals, and medical technology companies. His investments span early to late-stage ventures that aim to address critical unmet medical needs.
Kurt von Emster works as a Managing Partner at Abingworth, a prominent transatlantic venture capital firm specializing in life sciences investments.
